Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection

• Published in: Hepatology research Vol. 46; no. 13; pp. 1294 - 1303
• Main Authors: Ito, Jun, Suda, Goki, Yamamoto, Yoshiya, Nagasaka, Atsushi, Furuya, Ken, Kumagai, Kenichi, Kikuchi, Hideaki, Miyagishima, Takuto, Kobayashi, Tomoe, Kimura, Megumi, Yamasaki, Kazushi, Umemura, Machiko, Izumi, Takaaki, Tsunematsu, Seiji, Sato, Fumiyuki, Tsukuda, Yoko, Terashita, Katsumi, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya
• Format: Journal Article
• Language: English
• Published: Netherlands Blackwell Publishing Ltd 01.12.2016
• Subjects: direct-acting antiviral; hepatitis C virus; resistance-associated-variant; hepatitis C virus; resistance-associated-variant; direct-acting antiviral

Aim Sofosbuvir (SOF), a nucleotide analog pro‐drug, targets hepatitis C virus (HCV) NS5B polymerase and shows potential for treating HCV infection, given its high efficacy and good barrier to resistance. However, in addition to the rare resistant‐associated variant (RAV) of non‐structural protein NS...